Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**UrgoTul SSD** is a topical antibacterial wound-contact-layer medical device developed by Urgo Medical. It consists of a non-adherent polyester mesh incorporating Technology Lipido-Colloid with silver, including carboxymethylcellulose hydrocolloid, petrolatum, and silver sulfadiazine. In contact with wound exudate, the lipido-colloid matrix supports a moist wound environment and atraumatic dressing removal, while silver sulfadiazine provides local broad-spectrum antimicrobial activity. It has been used for second-degree burns and infected or infection-prone acute and chronic wounds, including leg ulcers and diabetic foot ulcers. ([hmpgloballearningnetwork.com](https://www.hmpgloballearningnetwork.com/site/wounds/content/comparison-two-silver-dressings-wound-management-pediatric-burns))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UrgoTul SSD.